查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1887170

镥-177 (Lu-177) 市场规模、占有率、成长及全球产业分析：依类型、应用和地区划分的洞察与预测 (2024-2032)

Lutetium-177 Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2024-2032
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 150 Pages | 商品交期: 请询问到货日

价格

镥-177 (Lu-177) 市场成长驱动因子

随着标靶放射性核种疗法在癌症治疗中日益重要，全球镥-177 (Lu-177) 市场正在快速扩张。根据最新评估，预计2024年市场规模将达到21.5亿美元，2025年达到27.3亿美元，到2032年将达到108.4亿美元。这意味着2025年至2032年的复合年增长率（CAGR）为21.8%。这一快速增长主要受癌症发病率上升、标靶治疗的日益普及以及新一代Lu-177放射性药物供应量增加的推动。

市场概览

镥-177是一种β射线放射性同位素，用于标靶放射性核种治疗，特别适用于神经内分泌肿瘤（NETs）和摄护腺癌，这两种肿瘤的发生率在全球范围内均呈上升趋势。镥-177能够特异性地与肿瘤受体结合，例如NETs中的生长抑素受体和前列腺癌中的PSMA（前列腺特异性抗原受体），从而实现将辐射精准地输送到癌细胞，同时保护健康组织。主要市场参与者包括诺华製药（Novartis AG）、兰特斯控股公司（Lantheus Holdings, Inc.）、泰利克斯製药公司（Telix Pharmaceuticals, Inc.）和雷迪製药诊断公司（Radiopharm Theranostics, Inc.），这些公司都在积极拓展其镥-177 (Lu-177)。

全球精准肿瘤学的兴起也推动了市场发展，放射性配体疗法 (RLT) 已成为传统疗法无效患者的重要治疗选择。

主要地区市场规模及趋势

2024年，北美在全球市场占主导地位，市占率高达82.79%。这主要得益于该地区较高的癌症发生率、完善的医保报销系统以及先进的放射性药物生产设施。预计到 2024 年，该地区的收入将达到 17.8 亿美元，其中美国凭藉 SHINE Technologies 位于简斯维尔的 Lu-177 工厂（北美最大的 Lu-177 工厂）等关键设施，引领着生产市场。

欧洲在 2024 年占第二大市场占有率，这得益于其强大的临床基础设施和标靶疗法的日益普及。英国萨顿核医治疗中心的启用进一步增强了该地区提供 Lu-177 PSMA 疗法的能力。

亚太地区预计将成为成长最快的地区，这主要得益于癌症病例的增加、临床试验的扩展以及各项合作计画的支持。 Radiopharm Theranostics 与 ANSTO 达成协议，供应未掺杂的钌-177，这凸显了对先进放射性药物的持续投资。

市场驱动因素

1.癌症发生率上升

前列腺癌、神经内分泌肿瘤和其他恶性肿瘤的发生率不断上升是推动市场成长的关键因素。仅在美国，预计到 2025 年将新增 313,780 例前列腺癌病例。镥-177 能够靶向输送 β 射线，使其成为晚期和难治性癌症的首选治疗方法。

2. 标靶治疗需求不断成长

标靶放射性核素治疗可减少副作用并改善治疗效果。 Lutathera（钌-177 多肽）和 Plavicto（钌-177 维匹博肽四环素）等产品的日益普及持续推动着市场成长。

市场限制因子

高额的治疗费用限制了中低收入国家的采用。单次注射 Pluvicto 的价格根据地区不同，从 5,000 美元到 12,000 美元不等，平均疗程需要六次注射。放射治疗基础设施的匮乏和不完善的报销体系进一步阻碍了其在全球的推广应用。

市场机会

推进临床研究带来了巨大的机会。在髓母细胞瘤、乳癌、胶质母细胞瘤和非小细胞肺癌 (NSCLC) 领域，使用镕-177 进行的临床试验数量不断增加，这正在扩大治疗范围。诸如 177Lu-omburtamab-DTPA 获得 RPDD（监管优先开发认定）等批准，正在拓展儿科肿瘤领域的治疗选择。

市场趋势

联合疗法

将钌-177与免疫疗法、DNA修復抑制剂和化疗合併应用正成为一大趋势。 Telix Pharmaceuticals 的 STARSTRUCK I 期临床试验（TLX250 与 peposertib 合併用药）代表治疗方案向协同增效方向的转变。

细分市场洞察

依药物分类

  • 由于神经内分泌肿瘤发生率的上升，Lutathera 在 2024 年占了市场主导地位。
  • 受前列腺癌治疗需求旺盛以及加拿大和欧洲医保报销政策改善的推动，PLUVICTO 正在快速扩张。

依年龄组

  • 2024年，由于65岁及以上男性前列腺癌的高发生率，成人占了最大的市场占有率。
  • 随着美国食品药物管理局（FDA）批准镥-177疗法用于12岁以上患者，儿科市场预计将快速成长。

依应用领域

  • 2024年，由于核准疗法数量不断增加以及治疗方案的广泛应用，前列腺癌市场占主导地位。
  • 由于临床研发的不断拓展，神经内分泌肿瘤预计将实现强劲成长。

依最终使用者

  • 2024年，在专业核医基础设施的推动下，医院市场占主导地位。

目录

第一章：引言

第二章：摘要整理

第三章：市场动态

  • 市场驱动因素
  • 市场限制因素
  • 市场机遇
  • 市场趋势

第四章：主要发现

  • 主要国家和地区主要疾病盛行率（2024 年）
  • 主要公司产品线分析
  • 主要公司新产品发布
  • 主要产业趋势（併购、合作等）
  • 新冠疫情对市场的影响

第五章：全球镥市场177 市场分析、洞察与预测 (2019-2032)

  • 市场分析、洞察与预测 - 依药物类型划分
    • Lutathera（镥-177 多他特）
    • Pruvict（镥-177 维匹博肽四氢西坦）
    • 其他
  • 市场分析、洞察与预测 - 依年龄组别划分
    • 成人
    • 儿科
  • 市场分析、洞察与预测 - 依应用领域划分
    • 神经内分泌肿瘤
    • 摄护腺癌
    • 其他
  • 市场分析、洞察与预测 - 依最终用户划分
    • 医院
    • 专科诊所
    • 其他
  • 市场分析、洞察与预测 - 依地区划分
    • 北美
    • 欧洲
    • 亚太地区
    • 世界其他地区

第六章：北美铠-177市场分析、洞察与预测（2019-2032）

  • 依国家划分
    • 美国
    • 加拿大

第七章：欧洲镥-177市场分析、洞察与预测（2019-2032）

  • 依国家划分
    • 德国
    • 美国王国
    • 法国
    • 义大利
    • 西班牙
    • 斯堪的纳维亚
    • 欧洲其他地区

第八章 亚太地区镥-177市场分析、洞察与预测（2019-2032）

  • 依国家划分
    • 中国
    • 日本
    • 印度
    • 澳大利亚
    • 东南亚
    • 亚太其他地区

第九章：世界其他地区镥-177市场分析、洞察与预测（2019-2032）

第十章：竞争分析

  • 全球市占率分析（2024）
  • 公司型材
    • 诺华公司
    • 泰利克斯製药股份有限公司
    • Ariceum 疗法
    • Radiopharm Theranostics 有限公司
    • Lantheus 控股公司
    • Y-mAbs Therapeutics, Inc.
    • 格莱泰瑞克斯
    • 锉
Product Code: FBI112740

Growth Factors of Lutetium-177 (Lu-177) Market

The global Lutetium-177 (Lu-177) market is experiencing rapid expansion as targeted radionuclide therapy gains global prominence in cancer treatment. According to the latest assessment, the market was valued at USD 2.15 billion in 2024, is projected to rise to USD 2.73 billion in 2025, and is expected to reach USD 10.84 billion by 2032, registering a strong CAGR of 21.8% during 2025-2032. This accelerated growth is driven by increasing cancer prevalence, expanding adoption of targeted therapies, and the growing availability of next-generation Lu-177 radiopharmaceuticals.

Market Overview

Lutetium-177 is a beta-emitting radioisotope used in targeted radionuclide therapy, particularly for neuroendocrine tumors (NETs) and prostate cancer, two cancer types with rising global incidence. Its unique ability to bind to tumor receptors-such as somatostatin receptors in NETs and PSMA in prostate cancer-allows precise delivery of radiation directly to cancer cells while preserving healthy tissues. Key market players include Novartis AG, Lantheus Holdings, Inc., Telix Pharmaceuticals, and Radiopharm Theranostics, all actively expanding their Lu-177 portfolios and production capabilities.

The market is also supported by the global shift toward precision oncology, where radioligand therapy (RLT) is emerging as a vital treatment option for patients who fail conventional therapies.

Market Size & Key Regional Insights

North America dominated the global market in 2024, holding a substantial 82.79% share, driven by high cancer prevalence, strong reimbursement frameworks, and the presence of advanced radiopharmaceutical manufacturing facilities. Regional revenue reached USD 1.78 billion in 2024, with the U.S. leading production due to major facilities like SHINE Technologies' Lu-177 plant in Janesville, the largest in North America.

Europe accounted for the second-largest market share in 2024, supported by robust clinical infrastructure and rising adoption of targeted therapies. The launch of the Nuclear Medicine Therapy Centre in Sutton, U.K., further strengthened the region's capabilities in administering Lu-177 PSMA therapy.

Asia Pacific is projected to be the fastest-growing region, driven by rising cancer cases, expanding clinical trials, and supportive collaboration initiatives. Partnerships such as Radiopharm Theranostics' agreement with ANSTO to supply non-carrier-added Lu-177 highlight ongoing investments in advanced radiopharmaceuticals.

Market Drivers

1. Rising Cancer Prevalence

The increasing incidence of prostate cancer, neuroendocrine tumors, and other malignancies is a primary growth driver. In the U.S. alone, 313,780 new prostate cancer cases are estimated for 2025. Lu-177's ability to deliver targeted beta radiation makes it a preferred therapy for advanced and treatment-resistant cancers.

2. Growing Demand for Targeted Treatment

Targeted radionuclide therapy reduces side effects and improves treatment outcomes. Increasing adoption of products like LUTATHERA (Lu-177 dotatate) and PLUVICTO (Lu-177 vipivotide tetraxetan) continues to fuel market expansion.

Market Restraints

High treatment costs restrict adoption in lower-middle-income countries. A single dose of Pluvicto can cost USD 5,000-12,000 depending on the region, with an average treatment regimen requiring six doses. Limited radiotherapy infrastructure and insufficient reimbursement policies further challenge global adoption.

Market Opportunities

Growing clinical research presents significant opportunities. Increasing numbers of clinical trials on Lu-177 for medulloblastoma, breast cancer, glioblastoma, and NSCLC are widening the therapeutic scope. Regulatory approvals-such as the RPDD for 177Lu-omburtamab-DTPA-are expanding treatment options into pediatric oncology.

Market Trends

Combination Therapy Integration

Combining Lu-177 with immunotherapy, DNA-repair inhibitors, and chemotherapy is emerging as a key trend. Telix Pharmaceuticals' STARSTRUCK Phase I trial combining TLX250 with peposertib exemplifies this shift toward synergistic treatment options.

Segmentation Insights

By Drug

  • LUTATHERA dominated in 2024 due to rising neuroendocrine tumor incidence.
  • PLUVICTO is expanding rapidly, driven by high demand for prostate cancer therapeutics and improving reimbursement access in Canada and Europe.

By Age Group

  • Adults held the largest share in 2024 due to high prostate cancer prevalence among men aged 65+.
  • Pediatrics is expected to grow rapidly following FDA approvals for Lu-177 therapies in children aged 12+.

By Application

  • Prostate cancer led the market in 2024 due to increased approvals and treatment availability.
  • Neuroendocrine tumors expected strong growth driven by expanding clinical development.

By End-User

  • Hospitals dominated the market in 2024 due to specialized nuclear medicine infrastructure.

Conclusion

With its market value rising from USD 2.15 billion in 2024 to USD 10.84 billion by 2032, the Lutetium-177 market is poised for transformational growth. Increasing cancer incidence, expanding radioligand therapy approvals, and strong regional production capabilities position Lu-177 as a cornerstone in the future of precision oncology.

Segmentation By Drug

  • LUTATHERA (lutetium Lu 177 dotatate)
  • PLUVICTO (lutetium Lu 177 vipivotide tetraxetan)
  • Others

By Age Group

  • Adults
  • Pediatrics

By Application

  • Neuroendocrine Tumor
  • Prostate Cancer
  • Others

By End-User

  • Hospitals
  • Specialty Clinics
  • Others

By Region

  • North America (By Drug, Age Group, Application, End-User, and Country)
    • U.S.
    • Canada
  • Europe ( By Drug, Age Group, Application, End-User, and Country/Sub-region)
    • Germany
    • U.K.
    • France
    • Spain
    • Italy
    • Rest of Europe
  • Asia Pacific ( By Drug, Age Group, Application, End-User, and Country/Sub-region)
    • China
    • Japan
    • India
    • Australia
    • Rest of Asia Pacific
  • Rest of the World ( By Drug, Age Group, Application, and End-User)

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
  • 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Market Trends

4. Key Insights

  • 4.1. Prevalence of Key Diseases, By Key Countries/Regions, 2024
  • 4.2. Pipeline Analysis, by Key Players
  • 4.3. New Product Launches, by Key Players
  • 4.4. Key Industry Developments (Mergers, Acquisitions, Partnerships, etc.)
  • 4.5. Impact of COVID-19 on the Market

5. Global Lutetium-177 Market Analysis, Insights and Forecast, 2019-2032

  • 5.1. Market Analysis, Insights and Forecast - By Drug
    • 5.1.1. LUTATHERA (lutetium Lu 177 dotatate)
    • 5.1.2. PLUVICTO (lutetium Lu 177 vipivotide tetraxetan)
    • 5.1.3. Others
  • 5.2. Market Analysis, Insights and Forecast - By Age Group
    • 5.2.1. Adults
    • 5.2.2. Pediatrics
  • 5.3. Market Analysis, Insights and Forecast - By Application
    • 5.3.1. Neuroendocrine Tumors
    • 5.3.2. Prostate Cancer
    • 5.3.3. Others
  • 5.4. Market Analysis, Insights and Forecast - By End-User
    • 5.4.1. Hospitals
    • 5.4.2. Specialty Clinics
    • 5.4.3. Others
  • 5.5. Market Analysis, Insights and Forecast - Region
    • 5.5.1. North America
    • 5.5.2. Europe
    • 5.5.3. Asia Pacific
    • 5.5.4. Rest of the World

6. North America Lutetium-177 Market Analysis, Insights and Forecast, 2019-2032

  • 6.1. Market Analysis, Insights and Forecast - By Drug
    • 6.1.1. LUTATHERA (lutetium Lu 177 dotatate)
    • 6.1.2. PLUVICTO (lutetium Lu 177 vipivotide tetraxetan)
    • 6.1.3. Others
  • 6.2. Market Analysis, Insights and Forecast - By Age Group
    • 6.2.1. Adults
    • 6.2.2. Pediatrics
  • 6.3. Market Analysis, Insights and Forecast - By Application
    • 6.3.1. Neuroendocrine Tumors
    • 6.3.2. Prostate Cancer
    • 6.3.3. Others
  • 6.4. Market Analysis, Insights and Forecast - By End-User
    • 6.4.1. Hospitals
    • 6.4.2. Specialty Clinics
    • 6.4.3. Others
  • 6.5. Market Analysis, Insights and Forecast - By Country
    • 6.5.1. U.S.
    • 6.5.2. Canada

7. Europe Lutetium-177 Market Analysis, Insights and Forecast, 2019-2032

  • 7.1. Market Analysis, Insights and Forecast - By Drug
    • 7.1.1. LUTATHERA (lutetium Lu 177 dotatate)
    • 7.1.2. PLUVICTO (lutetium Lu 177 vipivotide tetraxetan)
    • 7.1.3. Others
  • 7.2. Market Analysis, Insights and Forecast - By Age Group
    • 7.2.1. Adults
    • 7.2.2. Pediatrics
  • 7.3. Market Analysis, Insights and Forecast - By Application
    • 7.3.1. Neuroendocrine Tumors
    • 7.3.2. Prostate Cancer
    • 7.3.3. Others
  • 7.4. Market Analysis, Insights and Forecast - By End-User
    • 7.4.1. Hospitals
    • 7.4.2. Specialty Clinics
    • 7.4.3. Others
  • 7.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 7.5.1. Germany
    • 7.5.2. U.K.
    • 7.5.3. France
    • 7.5.4. Italy
    • 7.5.5. Spain
    • 7.5.6. Scandinavia
    • 7.5.7. Rest of Europe

8. Asia Pacific Lutetium-177 Market Analysis, Insights and Forecast, 2019-2032

  • 8.1. Market Analysis, Insights and Forecast - By Drug
    • 8.1.1. LUTATHERA (lutetium Lu 177 dotatate)
    • 8.1.2. PLUVICTO (lutetium Lu 177 vipivotide tetraxetan)
    • 8.1.3. Others
  • 8.2. Market Analysis, Insights and Forecast - By Age Group
    • 8.2.1. Adults
    • 8.2.2. Pediatrics
  • 8.3. Market Analysis, Insights and Forecast - By Application
    • 8.3.1. Neuroendocrine Tumors
    • 8.3.2. Prostate Cancer
    • 8.3.3. Others
  • 8.4. Market Analysis, Insights and Forecast - By End-User
    • 8.4.1. Hospitals
    • 8.4.2. Specialty Clinics
    • 8.4.3. Others
  • 8.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 8.5.1. China
    • 8.5.2. Japan
    • 8.5.3. India
    • 8.5.4. Australia
    • 8.5.5. Southeast Asia
    • 8.5.6. Rest of Asia Pacific

9. Rest of the World Lutetium-177 Market Analysis, Insights and Forecast, 2019-2032

  • 9.1. Market Analysis, Insights and Forecast - By Drug
    • 9.1.1. LUTATHERA (lutetium Lu 177 dotatate)
    • 9.1.2. PLUVICTO (lutetium Lu 177 vipivotide tetraxetan)
    • 9.1.3. Others
  • 9.2. Market Analysis, Insights and Forecast - By Age Group
    • 9.2.1. Adults
    • 9.2.2. Pediatrics
  • 9.3. Market Analysis, Insights and Forecast - By Application
    • 9.3.1. Neuroendocrine Tumors
    • 9.3.2. Prostate Cancer
    • 9.3.3. Others
  • 9.4. Market Analysis, Insights and Forecast - By End-User
    • 9.4.1. Hospitals
    • 9.4.2. Specialty Clinics
    • 9.4.3. Others

10. Competitive Analysis

  • 10.1. Global Market Share Analysis (2024)
  • 10.2. Company Profiles
    • 10.2.1. Novartis AG
      • 10.2.1.1. Overview
      • 10.2.1.2. Products
      • 10.2.1.3. SWOT Analysis
      • 10.2.1.4. Recent Developments
      • 10.2.1.5. Strategies
      • 10.2.1.6. Financials (Based on Availability)
    • 10.2.2. Telix Pharmaceuticals Limited
      • 10.2.2.1. Overview
      • 10.2.2.2. Products
      • 10.2.2.3. SWOT Analysis
      • 10.2.2.4. Recent Developments
      • 10.2.2.5. Strategies
      • 10.2.2.6. Financials (Based on Availability)
    • 10.2.3. Ariceum Therapeutics
      • 10.2.3.1. Overview
      • 10.2.3.2. Products
      • 10.2.3.3. SWOT Analysis
      • 10.2.3.4. Recent Developments
      • 10.2.3.5. Strategies
      • 10.2.3.6. Financials (Based on Availability)
    • 10.2.4. Radiopharm Theranostics Limited
      • 10.2.4.1. Overview
      • 10.2.4.2. Products
      • 10.2.4.3. SWOT Analysis
      • 10.2.4.4. Recent Developments
      • 10.2.4.5. Strategies
      • 10.2.4.6. Financials (Based on Availability)
    • 10.2.5. Lantheus Holdings, Inc.
      • 10.2.5.1. Overview
      • 10.2.5.2. Products
      • 10.2.5.3. SWOT Analysis
      • 10.2.5.4. Recent Developments
      • 10.2.5.5. Strategies
      • 10.2.5.6. Financials (Based on Availability)
    • 10.2.6. Y-mAbs Therapeutics, Inc.
      • 10.2.6.1. Overview
      • 10.2.6.2. Products
      • 10.2.6.3. SWOT Analysis
      • 10.2.6.4. Recent Developments
      • 10.2.6.5. Strategies
      • 10.2.6.6. Financials (Based on Availability)
    • 10.2.7. GLYTHERIX
      • 10.2.7.1. Overview
      • 10.2.7.2. Products
      • 10.2.7.3. SWOT Analysis
      • 10.2.7.4. Recent Developments
      • 10.2.7.5. Strategies
      • 10.2.7.6. Financials (Based on Availability)
    • 10.2.8. Curium
      • 10.2.8.1. Overview
      • 10.2.8.2. Products
      • 10.2.8.3. SWOT Analysis
      • 10.2.8.4. Recent Developments
      • 10.2.8.5. Strategies
      • 10.2.8.6. Financials (Based on Availability)

List of Tables

  • Table 1: Global Lutetium-177 Market Revenue (USD billion) Forecast, by Drug, 2019-2032
  • Table 2: Global Lutetium-177 Market Revenue (USD billion) Forecast, by Age Group, 2019-2032
  • Table 3: Global Lutetium-177 Market Revenue (USD billion) Forecast, by Application, 2019-2032
  • Table 4: Global Lutetium-177 Market Revenue (USD billion) Forecast, by End-User, 2019-2032
  • Table 5: Global Lutetium-177 Market Revenue (USD billion) Forecast, by Region, 2019-2032
  • Table 6: North America Lutetium-177 Market Revenue (USD billion) Forecast, by Drug, 2019-2032
  • Table 7: North America Lutetium-177 Market Revenue (USD billion) Forecast, by Age Group, 2019-2032
  • Table 8: North America Lutetium-177 Market Revenue (USD billion) Forecast, by Application, 2019-2032
  • Table 9: North America Lutetium-177 Market Revenue (USD billion) Forecast, by End-User, 2019-2032
  • Table 10: North America Lutetium-177 Market Revenue (USD billion) Forecast, By Country, 2019-2032
  • Table 11: Europe Lutetium-177 Market Revenue (USD billion) Forecast, by Drug, 2019-2032
  • Table 12: Europe Lutetium-177 Market Revenue (USD billion) Forecast, by Age Group, 2019-2032
  • Table 13: Europe Lutetium-177 Market Revenue (USD billion) Forecast, by Application, 2019-2032
  • Table 14: Europe Lutetium-177 Market Revenue (USD billion) Forecast, by End-User, 2019-2032
  • Table 15: Europe Lutetium-177 Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2019-2032
  • Table 16: Asia Pacific Lutetium-177 Market Revenue (USD billion) Forecast, by Drug, 2019-2032
  • Table 17: Asia Pacific Lutetium-177 Market Revenue (USD billion) Forecast, by Age Group, 2019-2032
  • Table 18: Asia Pacific Lutetium-177 Market Revenue (USD billion) Forecast, by Application, 2019-2032
  • Table 19: Asia Pacific Lutetium-177 Market Revenue (USD billion) Forecast, by End-User, 2019-2032
  • Table 20: Asia Pacific Lutetium-177 Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2019-2032
  • Table 21: Rest of the World Lutetium-177 Market Revenue (USD billion) Forecast, by Drug, 2019-2032
  • Table 22: Rest of the World Lutetium-177 Market Revenue (USD billion) Forecast, by Age Group, 2019-2032
  • Table 23: Rest of the World Lutetium-177 Market Revenue (USD billion) Forecast, by Application, 2019-2032
  • Table 24: Rest of the World Lutetium-177 Market Revenue (USD billion) Forecast, by End-User, 2019-2032
  • Table 25: Rest of the World Lutetium-177 Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2019-2032

List of Figures

  • Figure 1: Global Lutetium-177 Market Revenue Breakdown (USD billion, %) by Region, 2024 & 2032
  • Figure 2: Global Lutetium-177 Market Value Share (%), by Drug, 2024 & 2032
  • Figure 3: Global Lutetium-177 Market Value Share (%), by Age Group, 2024 & 2032
  • Figure 4: Global Lutetium-177 Market Value Share (%), by Application, 2024 & 2032
  • Figure 5: Global Lutetium-177 Market Value Share (%), by End-User, 2024 & 2032
  • Figure 6: North America Lutetium-177 Market Value (USD billion), by Drug, 2024 & 2032
  • Figure 7: North America Lutetium-177 Market Value Share (%), by Drug, 2024
  • Figure 8: North America Lutetium-177 Market Value (USD billion), by Age Group, 2024 & 2032
  • Figure 9: North America Lutetium-177 Market Value Share (%), by Age Group, 2024
  • Figure 10: North America Lutetium-177 Market Value (USD billion), by Application, 2024 & 2032
  • Figure 11: North America Lutetium-177 Market Value Share (%), by Application, 2024
  • Figure 12: North America Lutetium-177 Market Value (USD billion), by End-User, 2024 & 2032
  • Figure 13: North America Lutetium-177 Market Value Share (%), by End-User, 2024
  • Figure 14: North America Lutetium-177 Market Value (USD billion), By Country, 2024 & 2032
  • Figure 15: North America Lutetium-177 Market Value Share (%), By Country, 2024
  • Figure 16: Europe Lutetium-177 Market Value (USD billion), by Drug, 2024 & 2032
  • Figure 17: Europe Lutetium-177 Market Value Share (%), by Drug, 2024
  • Figure 18: Europe Lutetium-177 Market Value (USD billion), by Age Group, 2024 & 2032
  • Figure 19: Europe Lutetium-177 Market Value Share (%), by Age Group, 2024
  • Figure 20: Europe Lutetium-177 Market Value (USD billion), by Application, 2024 & 2032
  • Figure 21: Europe Lutetium-177 Market Value Share (%), by Application, 2024
  • Figure 22: Europe Lutetium-177 Market Value (USD billion), by End-User, 2024 & 2032
  • Figure 23: Europe Lutetium-177 Market Value Share (%), by End-User, 2024
  • Figure 24: Europe Lutetium-177 Market Value (USD billion), By Country/ Sub-region, 2024 & 2032
  • Figure 25: Europe Lutetium-177 Market Value Share (%), By Country/ Sub-region, 2024
  • Figure 26: Asia Pacific Lutetium-177 Market Value (USD billion), by Drug, 2024 & 2032
  • Figure 27: Asia Pacific Lutetium-177 Market Value Share (%), by Drug, 2024
  • Figure 28: Asia Pacific Lutetium-177 Market Value (USD billion), by Age Group, 2024 & 2032
  • Figure 29: Asia Pacific Lutetium-177 Market Value Share (%), by Age Group, 2024
  • Figure 30: Asia Pacific Lutetium-177 Market Value (USD billion), by Application, 2024 & 2032
  • Figure 31: Asia Pacific Lutetium-177 Market Value Share (%), by Application, 2024
  • Figure 32: Asia Pacific Lutetium-177 Market Value (USD billion), by End-User, 2024 & 2032
  • Figure 33: Asia Pacific Lutetium-177 Market Value Share (%), by End-User, 2024
  • Figure 34: Asia Pacific Lutetium-177 Market Value (USD billion), By Country/ Sub-region, 2024 & 2032
  • Figure 35: Asia Pacific Lutetium-177 Market Value Share (%), By Country/ Sub-region, 2024
  • Figure 36: Rest of the World Lutetium-177 Market Value (USD billion), by Drug, 2024 & 2032
  • Figure 37: Rest of the World Lutetium-177 Market Value Share (%), by Drug, 2024
  • Figure 38: Rest of the World Lutetium-177 Market Value (USD billion), by Age Group, 2024 & 2032
  • Figure 39: Rest of the World Lutetium-177 Market Value Share (%), by Age Group, 2024
  • Figure 40: Rest of the World Lutetium-177 Market Value (USD billion), by Application, 2024 & 2032
  • Figure 41: Rest of the World Lutetium-177 Market Value Share (%), by Application, 2024
  • Figure 42: Rest of the World Lutetium-177 Market Value (USD billion), by End-User, 2024 & 2032
  • Figure 43: Rest of the World Lutetium-177 Market Value Share (%), by End-User, 2024
  • Figure 44: Rest of the World Lutetium-177 Market Value (USD billion), By Country/ Sub-region, 2024 & 2032
  • Figure 45: Rest of the World Lutetium-177 Market Value Share (%), By Country/ Sub-region, 2024

Figure 46: Global Lutetium-177 Market Share (%), By Company, 2024